ClinicalTrials.Veeva

Menu

Adductor Canal Block and Arthroscopic Knee Surgery, High Pain Responders

G

Glostrup University Hospital, Copenhagen

Status and phase

Completed
Phase 4

Conditions

Arthroscopic Knee Surgery

Treatments

Procedure: Intervention group, block no. 1 - Ropivacain
Procedure: Control group: 1. block - saline

Study type

Interventional

Funder types

Other

Identifiers

NCT02001662
H-3-2013-039 (Other Identifier)
2013-000663-83 (EudraCT Number)
SM3-ME-13

Details and patient eligibility

About

The investigators want to explore the analgesic effect of Adductor Canal Blockade (a peripheral nerve block) in high pain responding patients after arthroscopic knee surgery. The investigators hypothesize that the nerve block will have an abrupt analgesic effect.

Enrollment

50 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Arthroscopic knee surgery, if reconstruction of Anterior Cruciate Ligament only hamstring graft 18-80 years of age BMI 18-40 ASA I-III written Consent

Exclusion criteria

Unable to communicate in danish, allergic reactions toward any study medication pregnancy alcohol/drug abuse daily opioid consumption scin infection (injection site)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Quadruple Blind

50 participants in 2 patient groups

Intervention group, block no. 1 - Ropivacain
Experimental group
Description:
Adductor-Canal-Block no.1: 30mL ropivacaine (7.5 mg/ml) when postoperative VAS-score is \> 40mm (on a 0-100 mm VAS-scale) during a 45 degree active flexion of the knee. Adductor-Canal-Block no.2: after 45 min (t45) - 30mL isotonic saline.
Treatment:
Procedure: Intervention group, block no. 1 - Ropivacain
Control group, block no. 1 - saline
Sham Comparator group
Description:
Adductor-Canal-Block no.1: 30mL isotonic saline when postoperative VAS-score is above 40mm (on a 0-100 mm VAS-scale) during a 45 degree active flexion of the knee. Adductor-Canal-Block no.2: after 45 min (t45) - 30mL ropivacaine (7.5 mg/ml)
Treatment:
Procedure: Control group: 1. block - saline

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems